ArticlePloS one2025
Immunophenotyping identifies key immune biomarkers for coronary artery disease through machine learning.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionThe differences among immune subtypes in coronary artery disease (CAD), their interrelationships, and the associated immune biomarkers remain incompletely understood.
methodsThe samples were collected from the GSE20686 and GSE42148 datasets for analysis. Principal component analysis (PCA) and Gene Set Variation Analysis (GSVA) were performed on the subtypes. Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) analyses were used to determine functional and pathways in CAD. Machine learning models were constructed for CAD prediction. Model validation was performed using GSE56885 and GSE71226 datasets. The expression and function of the identified genes were evaluated using immunohistochemistry, CCK-8 assays, wound healing assays, and Transwell invasion assays.
resultsMultiple immune cells showed correlations with CAD samples. Two immune cell subtypes were identified, with significant differences in programmed cell death-ligand (PD-L1) expression, immune scores, and stromal scores between subtypes (P < 0.05). Three CAD hub genes were identified by WGCNA. GO analysis revealed enrichment in Biological Process (BP) and Molecular Function (MF). Among the several machine learning models, the RF model was selected based on combining parameters. The model mainly included two CAD immune marker genes, AKT1 and PTK2B. Differential expression of AKT1 and PTK2B was observed in cardiac myocytes. Inhibition of PTK2B suppressed cell proliferation and invasion, and induced apoptosis in HUVEC cells.
conclusionImmunophenotyping revealed an association between CAD and PD-L1. AKT1 and PTK2B were identified as key disease signature genes, which may hold clinical significance for the diagnosis, prognostic assessment and treatment of CAD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.